Overview |
bs-19463R-Cy3 |
PSMC3 Polyclonal Antibody, Cy3 Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Xenopus laevis |
Dog, Cow, Horse |
Specifications |
Cy3 |
Rabbit |
KLH conjugated synthetic peptide derived from human PSMC3 |
212-220/439 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
5702 |
P17980 |
Cytoplasm, Nucleus |
26S protease regulatory subunit 6A; 26S proteasome AAA-ATPase subunit RPT5; Human immunodeficiency virus tat transactivator binding protein 1; MGC8487; Proteasome (prosome macropain) 26S subunit ATPase 3; Proteasome 26S ATPase subunit 3; Proteasome 26S subunit ATPase 3; Proteasome subunit P50; PRS6A_HUMAN; PSMC 3; PSMC3; Tat binding protein 1; TAT-binding protein 1; TBP-1; TBP1. |
The 26S protease is involved in the ATP-dependent degradation of ubiquitinated proteins. The regulatory (or ATPase) complex confers ATP dependency and substrate specificity to the 26S complex (By similarity). In case of HIV-1 infection, suppresses Tat-mediated transactivation. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |